Novartis drug Pacibekitug cuts inflammation, testing heart impact

Novartis' newly acquired drug, Pacibekitug, significantly reduced inflammation markers in a new study. Researchers are now testing if this reduction directly translates to improved heart health outcomes for patients. This is a big bet on inflammation as a core driver for cardiovascular disease.